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ChildEtiology and serotyping of parapneumonic effusion (PPE) and the impact of vaccination was evaluated
over a 12-year period, before and after the PCV13 introduction (2011) for Italian children From 0 to
16 years of age.
Five hundred and two children were evaluated; 226 blood and 356 pleural fluid samples were obtained
and tested using Realtime-PCR and culture. In the pre-PCV13 era S. pneumoniae was the most frequent
pathogen identified (64/90; 71.1%) with a large predominance of serotypes 1 (42.4%), 3 (23.7%), 7F
(5.1%) and 19A (11.9%).
The impact of vaccination, calculated on children 0–8 years of age, demonstrated a significant reduc-
tion of PPE: with an incidence rate of 2.82 (95%CL 2.32–3.41) in the pre-PCV13 era and an age-
standardized rate (ASR) of 0.66 (95% CL 0.37–1.99) in the post-PCV13 era, p < 0.0001. No increase in
non-PCV13 serotypes was recorded. S. pneumoniae remained the most frequent pathogen identified in
the post-PCV13 era in unvaccinated children with an unchanged serotype distribution: respectively
26/66 (39.4%), 25/66 (37.9%), 5/66 (7.6%), and 4/66 (6.1%) for 1, 3, 7F and 19A. On the other hand 7F
and 19A disappeared in vaccinated children and serotype 1 and 3 decreased by 91.8% and 31.5%, respec-
tively. Realtime PCR was significantly more sensitive than culture both in pleural fluid (79.7% vs 12.5%)
and in blood (17.8% vs 7.4%).
In conclusion, our findings indicate that routine immunization with PCV13 has significantly reduced
the burden of childhood PPE in vaccinated children, without increasing PPE due to other bacteria and
without serotype shift. Moreover, the impact of PCV13 may be underestimated due to the increase in
pneumococcal surveillance in Italy. Data has also shown that Real-time PCR is an essential tool to better
define the etiology of PPE and to monitor vaccination plans. Longer studies will be necessary to evaluate
the role of herd protection in PPE prevention.
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Parapneumonic effusion (PPE) and pleural empyema (PE) are
severe complications of community-acquired pneumonia (CAP)
[1]. Over the last twenty years, a marked increase in the
worldwide incidence of complicated pneumonia both in children
and adults has been described [2,3]. Streptococcus pneumoniae is
the main causal agent of complicated pneumonia in childhood
[4].
The introduction of 7-valent pneumococcal conjugate vaccine
(PCV7) into pediatric immunization programs has led to a dramatic
reduction in overall and PCV7-type incidence of pneumonia and
invasive pneumococcal disease (IPD). This benefit has also been
observed among unvaccinated age groups in countries where
PCV-7 is routinely used, which suggests that PCV-7 provides herd
protection [5,6].
Despite this apparent benefit, the empyema-associated hospi-
talization rates have increased over time [7], mainly due to non
PCV-7 serotypes such as 1, 3, 7F, and 19A [4,8].
The introduction of 13-valent pneumococcal conjugate vaccine
(PCV13) has further reduced the IPD incidence in childhood in
many countries [9–12]. A decrease in empyema incidence [13]
and hospitalization rates [14–16] of children after the introduction
of PCV13 has recently been reported, but the role of pneumococcal
serotypes in this evolution trend is still unclear. Moreover, data are
still lacking on herd-protection or a shift to other etiologies in long-
term studies in the PCV13 era.
The aims of our study were to describe the etiology of PPE and
PE in Italian children over a period of ten-years, to evaluate the
impact of pneumococcal conjugate vaccination using a
population-based molecular surveillance, and to determine the
sensitivity of RT-PCR compared to the culture method in the diag-
nosis of PPE.2. Patients and methods
2.1. Study design
Our observational study evaluated retrospectively all children
0–16 years of age included into the national Molecular Surveil-
lance Register and who had been admitted to Italian hospitals
with the diagnosis of PPE complicating CAP from September
2006 to October 2018. The Molecular Surveillance Register was
opened at the Immunology and Infectious Diseases Lab, Meyer
Children’s Hospital, Florence, Italy, (hereinafter ‘‘central Lab”) in
2006 and has been expanded with dedicated funds from the Ital-
ian Center for Disease Control (CCM) [17]. All pediatric hospitals
or pediatric units in Italy were invited to participate in the regis-
ter. To include a patient in the register, at least one biological
sample had to be tested at the central Lab by using Realtime-
PCR. A culture-based test was not a criterion for inclusion but cul-
ture results were recorded when available. Available clinical and
laboratory data were also recorded, using a standardized report
form.
Children with severe concomitant diseases (i.e. cystic fibrosis,
immunodeficiency, neurological impairment) or suspected noso-
comially acquired infections (i.e. hospitalization and/or admis-
sion to emergency departments and/or access to ambulatory
services over the previous 14 days) were excluded from the
study. The study was approved by the Institutional
Review Board. All data and samples included in this study were
collected as part of the routine clinical activity and evaluated
retrospectively and anonymously in the study. For this reason,
a specific approval by the regional ethical committee was not
required.2.2. Case definition
Patients with clinical suspicion of pneumonia complicated by
PPE/PE were evaluated. Pneumonia was suspected on the basis of
clinical signs such as abnormal breath sounds and/or tachypnea;
confirmation was obtained by chest X-ray and/or chest ultrasono-
gram and/or computed tomography. A pediatric pulmonologist
with experience in radiology, in collaboration with radiologists,
evaluated radiographs and assigned standardized and mutually
exclusive diagnoses of focal, segmental, or lobar consolidation with
or without pleural effusion, interstitial pneumonia, atelectasis, or
necrotizing pneumonia, as previously described [8,18]. In particu-
lar, diagnosis of parapneumonic effusion (PPE) was assigned in the
presence of loculated pleural fluid on a chest X-ray, a chest ultra-
sonogram, or a computed tomography [19]. Diagnosis of pleural
empyema (PE) was assigned in the presence of pleural fluid param-
eters consistent with empyema [19]. Only patients with a con-
firmed radiological diagnosis of PPE/PE were included in the
study. Clinical information was sent, together with biological sam-
ples, using a standardized report form for each patient. Updates on
the clinical conditions of the patients and on culture results were
obtained by phone interviews to the sending hospitals.
2.3. Laboratory methods
Laboratory confirmation was obtained by RT-PCR and/or culture
methods as previously described [8].
For culture purposes, standardized procedures were used for
collection and shipment of biological samples to local laboratories.
Samples for molecular tests were sent by participant centers to
the central Lab using an overnight freepost carrier and tests were
performed within 2 h of delivery. For routine diagnosis, a panel
of primers and probes for the following 14 pathogens was used:
Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus
influenzae, Escherichia coli, Klebsiella pneumoniae, Streptococcus
agalactiae, Listeria monocytogenes, Staphylococcus aureus, Strepto-
coccus pyogenes, Pseudomonas aeruginosa, Salmonella spp, Myco-
plasma pneumoniae, Fusobacterium spp, (the most frequent in
invasive bacterial diseases in Italy) and Adenovirus. Etiological
diagnosis was made if RT-PCR and/or culture was positive in blood
or pleural fluid as previously described [8]. When RT-PCR was neg-
ative for all primers/probes included in the panel, amplification
and sequencing of the 16S rRNA bacterial gene were performed.
All samples positive for S. pneumoniae were serotyped by RT-PCR
using 33 primer couples and probes. Part of the primer-probe sets
are published [8,19], the others are available upon request. As pre-
viously published [18], Realtime PCR reliability in pneumococcal
serotyping has been demonstrated by testing serotyped pneumo-
coccal isolates from ATCC as controls. Pneumococcal serotypes
were classified as PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, 23F),
PCV13 serotypes (PCV7 plus 1, 3, 5, 6A, 7F, 19A), and non-PCV13
serotypes (not included in the PCV13). If no increase in fluorescent
signal was observed after 40 cycles for any of the serotype-specific
primer/probe sets, in spite of a positive result with both RT-PCR
(lytA gene) and end-point PCR (cpsA gene), the sample was reported
as non-typeable.
2.4. Vaccine uptake
Mean vaccination coverage for PCV13 in Italian target popula-
tions in the post-PCV13 era was obtained from the Italian Ministry
of Health (http://www.salute.gov.it/portale/documentazione/p6_
2_8_3_1.jsp?lingua=italiano&id=20; accessed April 1, 2019) and is
shown in the supplementary file, Table 1. No catch-up campaign
for children >1 years of age was planned after the introduction of
PCV13.
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Since participation in the Molecular Surveillance Register and
in the present study was dependent on voluntary instead of
mandatory surveillance, the incidence of PPE cases calculated
using the whole Italian pediatric population as denominator
does not reflect the true incidence of disease in Italy but allows
the impact of the vaccination to be evaluated. The overall
incidence and incidence for each serotype in the pre- and
post-PCV13 eras were calculated as a crude incidence rate in
the pre-PCV13 era (reference population) and as an age stan-
dardized incidence rate (ASR) in the post-PCV13 era (study
population).
Since PCV13 was included in the vaccination schedule in the
last quarter of 2010, only children 0–8 years of age were evaluated
in the pre- vs post-PCV13 era comparison. Children 0–8 years of
age who were born before 2011 and had pneumococcal PPE either
before or after 2011 were considered as reference population and
were compared with children of the same age range born after
2011 (study population). Details are given in the supplementary
file, Tables 2 and 3
The number of samples received for molecular surveillance
from all Italian hospital for patients <16 years of age was evaluated
in order to ascertain potential bias associated with improvement of
surveillance that might interfere with the evaluation of the impact
of PCV13.2.6. Statistical analysis
Data were processed with the SPSS release 21 statistical package
and the freely available ‘‘epitools” R package (https://www.r-pro-
ject.org/). Results were expressed as mean and standard deviations
or as a median; p < 0.05 was considered to be statistically signifi-
cant and 95% confidence intervals were shown when appropriate.
Incidences were calculated as crude age-specific incidences and
age-standardized incidence rates (ASR). ASR was calculated
through direct age standardization considering the pre-PCV13 pop-
ulation as the reference population and the post-PCV13 population
as the study population. Confidence intervals were calculated using
the exactmethods. Differences between rateswere calculated using
the Rothman methods. Standardized incidence ratio (SIR) was cal-
culated as the ratio between the sum of observed cases of the
post-PCV13 era and the sum of expected cases of the post-PCV 13
era (see supplementary file for details). The Pearson chi-square test
or Fisher’s exact test were used to assess group differences in cate-
gorical variables. For comparison of two different etiologic tests
(with comparison of proportions) a two-sample test of proportions
was used to determine significance and confidence intervals.
Cohen’s kappa coefficient and the McNemar test were used to
measure agreement between tests.
For continuous variables, Student’s t test was used.3. Results
Data from 502 children with PPE were available (286 males,
57.0%; mean age, 5.61 ± 3.67 years; median age, 4.57 years, range
IQ, 3.05–7.44 years). Patients were recruited from regions uni-
formly distributed over the country and covering highly populated
areas in Italy, so that they represent 91.9% of the national popula-
tion <16 years of age (http://demo.istat.it). The number of samples
received for molecular surveillance from all Italian hospitals for
patients <16 years of age increased over the years (post-PCV13
era vs pre-PCv134 era: +102%). Because of this bias, the impact of
PCV13 on PPE/PE might be underestimated.3.1. Vaccine uptake
PCV13 was included in a national immunization plan with a 3-
dose-schedule (3-5-12 months) in replacement of PCV7 in the last
quarter of 2010. Mean annual vaccination coverage for PCV13 in
Italian target populations in the post-PCV13 era has always been
over 80% (http://www.salute.gov.it/portale/documentazione/p6_
2_8_3_1.jsp?lingua=italiano&id=20; accessed April 1, 2019; see
supplementary file, Table 1 for detailed data). No catch-up cam-
paign for children >1 years of age has been carried out since the
introduction of PCV13.
3.2. Etiological diagnosis
Overall, etiological diagnosis was achieved in 214/502 (42.6%)
patients. Pleural fluid and blood samples were obtained from 226
and 356 children, respectively. Pleural fluid was significantly more
informative than blood in revealing etiology: respectively 179/226
(79.2%) for pleural fluid and 67/356 (18.8%) for blood (difference
between proportions 0.60; p < 105; 95% CI 0.54–0.67). S. pneumo-
niae was the most frequent pathogen identified (156/214; 72.8%),
followed by Streptococcus pyogenes (22/214; 10.2%) and Staphylo-
coccus aureus (8/214; 3.7%). The distribution of all pathogens iden-
tified is shown in Fig. 1.
In the pre-PCV13 era (2006–2010), 239 cases of PPE were found.
Etiology was identified in 90/239 (37.6%) patients, and S. pneumo-
niae was found in 64/90 (71.1%).
In the post-PCV13 era (2011–2018), 263 cases of PPE were
found. Etiology was identified in 124 (47.1%). As in the pre-
PCV13 era, S. pneumoniae was the most frequent pathogen
(92/124; 74.2%). However, the large majority 75/92 (81.5%) of
affected children had not been vaccinated with PCV13: 58/92
(63.0%) because they were born before 2011, 17/92 (18.4%) due
to their young age (3.2%) or their parents’ decision (15.2%); on
the other hand 17/92 had received PCV13 (18.4%).
3.3. Streptococcus pneumoniae serotyping
RT-PCR analysis allowed serotyping in 140/151 (92.7%)
patients; in 5 patients the sample amount was not enough to per-
form serotyping. Serotype distribution in the pre-PCV13 era
(n = 59) and in the post-PCV13 era (n = 81) is shown in Fig. 2. In
the pre-PCV13 era, PCV13 serotypes accounted for 98.3%
(n = 57/59). Serotypes 1, 3, 7F and 19A were the most frequent
(n = 49; 83.0%).
In the post-PCV13 era, only serotypes 1 (2/15, 13.3%) and 3
(13/15 86.6%) were found present in children who experienced
pneumococcal PPE in spite of vaccination (n = 15/81) (Fig. 2). On
the other hand, the serotype distribution in children who had not
received the PCV13 vaccination, due to being born before PCV13
was available (n = 66/81), was as follows: PCV13 serotypes still
accounted for 92.4% (n = 61/66) with one case of serotype 14 and
serotypes 1, 3, 7F and 19A causing all other (60/61, 90.9%) cases.
The proportion of non-PCV13 serotypes did not significantly
increase over the years: 2/59 (3.4%) cases in the pre-PCV13 period
(one each serotype 8 and 20), and 5/81 (6.2%) in the post-PCV13
period (two serotypes 12 and one each serotype 24, 32, and 35F)
were found (p = 0.70).
3.4. The impact of vaccination (pre- vs post-PCV13 era)
The incidence of pneumococcal PPE/PE cases in children 0–
8 years of age born in the pre- or post-PCV13 era is shown in
Fig. 3. Data demonstrates a significant impact of vaccination with
a decrease in pneumococcal PPE in the post-PCV13 era. The Stan-
dardized Incidence Ratio (SIR) decreased (data and calculations
Fig. 1. Etiology of pleural empyema in 214 children <16 years of age.
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two groups, the crude incidence rate was 2.82 per 1,000,000
person-years (95% CL 2.32–3.41) for children born before 2011
while the ASR was 0.66 per 1,000,000 person-years (95% CL
0.37–1.99) for children born after 2011 and vaccinated with
PCV13; p < 0.0001 (Fig. 3).
The incidence rates of the most frequent serotypes in the pre- or
post-PCV13 era are shown in Fig. 4. In vaccinated children in the
post-PCv13 era, serotypes 19A and 7F completely disappeared, ser-
otype 1 decreased by 91.8% and serotype 3 decreased by 31.5%
(statistical analysis is shown in Fig. 4).3.5. Sensitivity of RT-PCR vs. Culture
RT-PCR analysis and culture on pleural fluid samples were pos-
itive respectively in 177/222 (79.7%) and 8/64 (12.5%) children.
Overall, in pleural fluid RT-PCR analysis was 6.4 times more sensi-
tive than culture in achieving etiological diagnosis (difference
between proportions 0.67; p < 105; 95% CI 0.58–0.77). RT-PCR
analysis and culture on blood samples were positive in 64/359
(17.8%) and 15/204 (7.4%) of children, respectively. Overall, in
blood samples RT-PCR analysis was 2.4 times more sensitive than
culture in achieving etiological diagnosis (difference between pro-
portions 0.11; p < 0.00058; 95% CI 0.05–0.16). The results did not
change in the subgroup of samples in which culture and RT-PCR
analyses, either on pleural fluid (n = 63) or in blood (n = 173) sam-
ples, were performed on the same sample (respectively for pleural
fluid OR 42.4, 95%CI 13.63–139.89; Cohen’s K coefficient 0.008,
McNemar p < 105; for blood OR 4.03, 95% 1.95–8.50; Cohen’s k
coefficient 0.162; McNemar p < 105).4. Discussion
To the best of our knowledge, the present study is one of the lar-
gest studies on children with PPE in Europe. Our study confirms
that, as in the USA and Australia [3,4], S. pneumoniae is the most
frequent pathogen involved in PPE (73%). A variety of other organ-
isms was detected by RT-PCR. After S. pneumoniae, S. pyogenes was
the next most common pathogen and that is consistent with the
results of a recent study in Canadian children [20].
By using the year 2011 as a watershed between the pre- and
post-PCV13 eras, the proportion of cases due to S. pneumoniae in
PPE was similar when the two periods were compared (71.1% vs
73.9%). However, over 85% of pneumococcal PPE diagnosed after
2011 occurred in children who had not received the PCV13 vacci-
nation, mainly because they were too old when PCV13 was
included in newborn vaccinations in Italy and no catch-up program
for older children had been planned in Italy, even though demon-
strated as highly effective in other countries.
Our study shows a significant impact of the PCV13 vaccination
on PPE complicating CAP: the age standardized incidence rate was
significantly lower in children born in the post-PCV13 era and vac-
cinated with PCV13 when compared to children born in the pre-
PCV13 era. That impact is probably even greater, since samples
received and diagnosed by the central Lab increased over time dur-
ing the study period and that bias might have obviously caused an
underestimation of the impact of PCV13.
Our data demonstrated a significant impact of the PCV13 vacci-
nation on the incidence of most frequent serotypes: in the post-
PCV13 era serotypes 7F and 19A completely disappeared, serotype
1 decreased by 92%, and serotype 3 by 32%. The lower impact of the
Fig. 2. Serotype distribution in 140 pediatric (0–16 years of age) pneumococcal PPE occurring before 2011 (A), occurring after 2011 in children not vaccinated or because they
were born before PCV13 was available (2011), or due to their young age or their parents’ decision(B), and occurring in children born after 2011 and vaccinated with PCV13(C).
The diameter of circles is proportional to the number of cases. Number of cases is not indicated where a single case for serogroup was found.
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ing: a similar study on pneumococcal pneumonia in the USA
demonstrated a decrease of 38% [16] and recent studies on other
IPD showed that PCV13 effectiveness against serotype 3 is lower
than other serotypes, such as 7F or 19A [9,10,21]. In addition, pre-
vention of pneumonia and its complications requires higher levels
of anti-capsular polysaccharide antibody concentration, which
may not be reached for some serotypes with the standard vaccina-
tion protocol [21]. On the other hand, the impact of PCV13 on other
invasive pneumococcal infections due to serotype 3 such as sepsis
or meningitis seems to be significantly higher (personal data,
submitted).
Data from previous studies on pediatric IPD showed a signifi-
cant overall reduction in invasive pneumococcal disease, while
data on serotype replacement (increased incidence of the non-
PCV13 serotypes) are conflicting. Evidence of increasing invasive
pneumococcal disease due to non-PCV13 serotypes has been found
in the UK and in Israel [10,22] while serotype replacement has not
been reported in the USA [23], where incidence of IPD due to non-
vaccine serotypes in young children has remained unchanged since
the introduction of PCV13. Data from the present study show that
serotype replacement was not observed in pediatric PPE in Italy.
One possible explanation is that, due to the known geographical
variations in serotype replacement [23], non-PCV13 serotypes are
not increasing in Italy. However, data obtained in the present study
in a specific disease (PPE/PE) cannot be generalized to all pediatric
IPD. Actually, other possible explanations for the lack of serotypereplacement in PPE/PE should also be considered and, particularly,
the fact that pneumococcal PPE are mainly caused by a limited
number of serotypes [24] -among them 1, 3 and 19A- which have
a strong tropism for lung and pleural tissue as demonstrated by
previous reports [2–4,8,24]. Emerging serotypes recently found in
other IPD might have a lesser tropism for lung and pleural tissue
and therefore their impact on PPE incidence could be limited. How-
ever, the number of non-vaccine serotypes are still too low to see a
significant difference and close monitoring of non PCV13 cases is
mandatory.
Data on PCV7 showed clear evidence of herd protection, with a
significant decrease in PCV7 serotypes in all age groups [6]. Differ-
ently from what has been shown with PCV7 [5,6], herd protection
for the six additional serotypes included in PCV13 (1, 3, 5, 6A, 7F,
19A) is debatable [25–27]. Our data show that, in non-vaccinated
children, the distribution of pneumococcal serotypes did not
change after the introduction of PCV13 and, at a first superficial
glance, that might suggest a lack of herd protection in non-
vaccinated groups. Actually, in non-vaccinated children, serotypes
1, 3, 7F, and 19A remained the most represented in the post-PCV13
era (83% before 2011, 90.9% after 2011). On the contrary, in the
limited number of children that experienced PE/PPE in spite of
the PCV13 vaccination, only serotype 1 (two cases) and 3 (thirteen
cases) were detected, showing a completely different distribution
of pneumococcal serotypes. However, it must be remarked that
even though the PCV13 coverage was high (over 85%) in Italian
newborns (target population) in the post-PCV13 era (http://
Fig. 3. Impact of PCV13 vaccination on pneumococcal PPE in children 0–8 years of age, according to age. Incidence is calculated as cases for million person years. Crude
incidence rate and 95% CL of pneumococcal PPE are shown in blue for children born before PCV13 was available; age standardized incidence rate (ASR) and 95% CL are shown
in orange for children born after PCV13 era and vaccinated with PCV13. Number of cases an p values are shown on bars. *p is calculated for overall incidence. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
C. Azzari et al. / Vaccine 37 (2019) 2704–2711 2709www.epicentro.iss.it/temi/vaccinazioni/dati_Ita), immunization
was only offered to newborns and no catch up programwas carried
out. Therefore, the proportion of vaccinated children in the 0–
16 years of age group was very limited (about 5–6% in the first year
after implementation of PCV13) and increased by the same amount
every year. For this reason, an impact of the vaccinated population
on the protection of older non-vaccinated children could not be
expected in the first years after PCV13 was introduced and should
be evaluated in a longer follow-up. Therefore, the evaluation of
herd protection was not included in the aims of the present study
and conclusions on that point cannot be drawn.
Pleural fluid analysis was significantly more sensitive than
blood in revealing etiology; this was not unexpected, since pneu-
monia is uncommonly associated with persistent bacteremia [8].
RT-PCR appeared significantly more sensitive than culture in
achieving etiologic diagnosis, both in blood (17.8% vs 7.4%) and
especially in pleural fluid samples (79.7% vs 12.5%), thus confirm-
ing the results of our and other authors’ previous reports
[8,12,28–31]. Early antibiotic therapy may have, in part, affected
the results [32], but other interfering factors associated with sam-
ple collection, shipment, and storage may also have contributed to
the low sensitivity of blood culture. Being DNA stable at room tem-
perature for a long time, RT-PCR suffers the effect of those factors
to a much lesser extent.
Our study has some limitations. First of all, since participation
to molecular surveillance is voluntary and not based on a manda-
tory surveillance, cases of PPE in hospitals not included in the pre-sent study might have occurred; therefore, the data does not reflect
the real incidence of PPE in Italy and the data cannot be compared
with incidences in other countries. However, the evaluation of real
PPE incidence was not the goal of the present study, which aimed
instead to evaluate the impact of the PCV13 vaccination on pedi-
atric PPE. In this regard, the present study -including 502 cases
of PPE and, among them, 214 with etiological diagnosis and
serotyping- was, to the best of our knowledge, the largest collec-
tion of pediatric PPE cases in Europe and allowed the change in eti-
ology and the impact of the PCV13 vaccination over a decade to be
evaluated.
Secondly, the number of samples received by the central Labo-
ratory increased by over 100% over time during the study period.
This increase, due to the increase in attention paid by clinicians
in Italy to the need for surveillance, confirms the data collected
by the National Institute of Health (http://old.iss.it/mabi/index.
php?lang=1&id=5&tipo=16, accessed April 1, 2019) as well as the
difficulties associated with regionalism in Healthcare. As a conse-
quence of surveillance improvement, diagnoses of monitored
infectious diseases (such as pneumococcal and meningococcal
infection) increased over time and that bias may reflect negatively
on the impact of PCV13 and its effectiveness can result
underestimated.
We are also aware of the fact that we included, in our molecular
surveillance, only 14 pathogens, so that other etiologies (bacterial
or viral) could have been missed. However, with the set of primer/
probes included in the study, it was possible to find the causative
Fig. 4. Impact of PCV13 vaccination on the frequency of the most frequent serotypes in children 0–8 years of age in Italy. Incidence is calculated as cases for million person
years. Crude incidence rate and 95% CL of pneumococcal PPE are shown in blue for children born before PCV13 was available; Age standardized incidence rate (ASR) and 95%
CL are shown in orange for children born after PCV13 era and vaccinated with PCV13. Number of cases and p values are shown on bars. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
2710 C. Azzari et al. / Vaccine 37 (2019) 2704–2711pathogen in about 80% of pleural fluids. Moreover, the use of 16S
gene sequencing, even if less sensitive than Realtime PCR because
based on an end-point PCR technology [19], could have found other
bacterial etiologies. Further studies will be necessary to evaluate
the role of viral infections or co-infections on PPE/PE epidemiology
in Italy.
In conclusion, our findings indicate that routine immunization
with PCV13 has significantly reduced the burden of childhood PPE
in vaccinated children, without increasing PPE due to other bacte-
ria and without a serotype shift. The reduction may be signifi-
cantly underestimated because of the improvement in the
surveillance all over the country. Data has also shown that
Real-time PCR in pleural fluids is an essential tool to better define
the etiology of PPE and to monitor vaccination plans, while longer
studies will be necessary to evaluate the importance of herd
protection.Funding
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